A5081108017- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Mechanisms and Therapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- PARP inhibition in cancer therapy
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Microtubule and mitosis dynamics
- Intraperitoneal and Appendiceal Malignancies
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Protein Degradation and Inhibitors
Magna Graecia University
2014-2024
Dulbecco Telethon Institute
2023-2024
Azienda Ospedaliero Universitario Mater Domini
2019-2023
San Salvatore Hospital
2013-2015
Objective The objective of this multicenter, observational, retrospective analysis was to evaluate the safety and efficacy sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) patients managed according common clinical practice Italy. Methods Data were retrieved by 7 sites. Triple-negative BC defined lack expression estrogen receptor (ER <1%), progesterone (PgR <1%) human-epidermal growth factor receptor-2 (HER2 0, 1+, 2+ ISH-not amplified) standard...
Abstract Background We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity against human xenografts in mice, and favorable toxicokinetics rats monkeys. Allometric interspecies scaling allowed us to define the first-in-class LNA-i-miR-221 safe starting dose for clinical translation. Methods In this first-in-human, open-label, dose-escalation phase...
Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients when combined chemotherapy. At present, while there rising attention bevacizumab-related adverse events and costs, no or biological markers have been identified validated for baseline patient selection. Preclinical findings suggest an important role myeloid-derived inflammatory cells, such as neutrophils monocytes, the development of...
Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss development of this innovative compound and report recent changing-practice results breast pancreatic cancer. A ground-breaking finding is demonstration that nab-paclitaxel can not only enhance activity reduce toxicity chromophore-diluted compound, but also exert diseases considered refractory to taxane-based This clinical major nanotechnologically modified...
Colorectal cancer (CRC) is one of the most common malignancies and a relevant cause cancer-related deaths worldwide. Dysregulation microRNA (miRNA) expression has been associated with development progression various cancers, including CRC. Among them, miR-221 emerged as an oncogenic driver, whose high poor patient prognosis. The present study was conceived to investigate anti-CRC activity silencing based on early clinical data achieved from first-in-human by our group. Going back bedside...
Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory (RRMM) remains a challenge; the rational choice of most appropriate regimen in this setting currently undefined. We performed systematic review 2 standard pairwise meta-analyses to evaluate efficacy regimens that have been directly compared with bortezomib or immunomodulatory imide drugs (IMiDs) head-to-head clinical trials network meta-analysis (NMA) determine relevance each on basis all...
Immune-checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor-1, is an emerging treatment for metastatic non-small lung cancer (mNSCLC). In order prolong patient survival, this requires continuous cross-priming of tumor derived-antigens supply fresh tumor-specific immune-effectors; phenomenon that may also trigger auto-immune-related adverse events (irAEs). The present study therefore investigated the prognostic value multiple autoimmunity-associated...
Background Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability kill target cells expressing specific antigen-derived epitope peptides bound homologue leukocyte antigen (HLA) molecules. currently an active but expensive therapeutic agent for metastatic non-small lung cancer (mNSCLC), producing, in some cases, immune-related adverse events (irAEs). At the...
Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small-Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies on a variety factors which may allow identification novel biomarkers. Presently, biomarkers are under investigation, including PD1/PDL1 axis, tumor mutational burden, and microbiota. latter is made bacteria other microorganisms hosted in our body. gut microbiota most represented has been involved...
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in EOC includes platinum salts paclitaxel with or without bevacizumab. The major prognostic factor response duration from end platinum-based treatment (platinum-free interval) about 10-0 % patients...
Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damaging response (DDR) has an established role disease pathobiology. Indeed, deregulation repair pathways may contribute to genomic instability, the establishment drug resistance genotoxic agents, escape from immune surveillance. On these bases, we evaluated different DDR MM investigated, for first time, direct immune-mediated anti-MM activity nucleotide excision (NER)-dependent agent trabectedin....
Taxane-related peripheral neuropathy (TrPN) is a dose-limiting toxicity with important interindividual variability. Genetic polymorphisms in absorption, distribution, metabolism, and excretion (ADME) genes may account for variability drug efficacy and/or toxicity. By the use of Affymetrix drug-metabolizing enzyme transporter microarray platform, retrospective case-control study, correlation between ADME polymorphic variants grades ≥ 2-3-TrPN was investigated. In breast cancer (BC) training...
The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, excretion (ADME)-related genes were evaluated to identify new potential predictive HCC patients. Five known angiogenesis-related genes, including VEGF-A, VEGF-C, HIF-1a, ANGPT2, NOS3, investigated 34 patients (9 responders 25 non-responders). A subgroup 23 was...
Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies to a variety factors which may allow identification novel biomarkers. Presently, biomarkers are under investigation, including PD1/PDL1 axis, tumor mutational burden, and Microbiota. This latter is made bacteria other microorganisms hosted in our body. gut microbiota most represented has been...
Background: Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 have led to improved survival of metastatic malignant melanoma patients. Due the mechanism action, these drugs are associated with a unique toxicity profile. Immune-related adverse events (irAEs) present wide clinical spectrum Achilles' heel immunotherapy. Immunomodulatory used for management irAEs can theoretically lead tumor escape. Cutaneous toxicities among most commonly irAEs. Case presentation: We report case 75...